Pediatric acute-onset neuropsychiatric syndrome

The Journal Lupus Publishes Investigator-Initiated Study Results Demonstrating Improved Executive Function in Patients with Systemic Lupus Erythematosus Following Use of Akili’s AKL-T01 Product Candidate

Retrieved on: 
Thursday, July 14, 2022
Software, Technology, General Health, Health, Technology, Lists of diseases, Prevalence, Government budget balance, MJ, University of Maryland Human–Computer Interaction Lab, Safety, Psychiatry, University of Colorado School of Medicine, JG, Communication, Pediatric acute-onset neuropsychiatric syndrome, SLE, Attention, ASD, Risk, Multiple sclerosis, National Jewish Health, Patient, Cognitive deficit, Ageing, Systematic review, Brain, COVID-19, Lupus, Cognitive disorder, Rheumatology, Autism spectrum, Monitor, Non-functional testing, Medicine, Degenerative disease, Discoid lupus erythematosus, WAIS-IV, SSME, Even and odd functions, Forward-looking statement, ADHD, MS, Research, Quality of life, University, Industry, Pharmaceutical industry, Medical device, Risk management, Neurology, Yolo Akili

Data from the study show that AKL-T01 resulted in significant improvement in motor speed and executive functions.

Key Points: 
  • Data from the study show that AKL-T01 resulted in significant improvement in motor speed and executive functions.
  • Further, the study investigated the ability of the product EVOTM Monitor5, built on the same technology platform, to serve as a rapid mobile assessment of cognitive function.
  • The results of this study in patients with SLE are consistent with the cognitive improvements seen in other studies after using our digital therapeutic.
  • Cognitive impairment in systemic lupus erythematosus is negatively related to social role participation and quality of life: a systematic review.

Geneuro Receives CHF 6.7 Million (EUR 6.4 Million) in Funding From the Swiss Government for the Development of Temelimab Against Long-COVID

Retrieved on: 
Monday, December 13, 2021
Science, Biotechnology, Research, Pharmaceutical, Health, Infectious Diseases, Clinical Trials, Other Health, Forward-looking statement, HERV-W, COVID, Technology, Symptoms of COVID-19, Company, FOPH, HIV disease progression rates, Severe acute respiratory syndrome coronavirus 2, Clinical trial, Euronext Paris, Genome, Brain, Public health, Association, Degenerative disease, Industry, Multiple sclerosis, COVID-19, Lancet, Rufus Herve Bacote, CEO, Swiss Federal Institute of Aquatic Science and Technology, Patient, Lymphocyte, Endothelium, Patent, Neurodegeneration, Alzheimer's disease, Blood, Long COVID, Pediatric acute-onset neuropsychiatric syndrome, Parkinson's disease, Lists of diseases, Pharmaceutical industry, Vaccine, Medical imaging, W-ENV and COVID-19, GeNeuro, W-ENV AND COVID-19, GENEURO

"We are extremely grateful for this funding from the FOPH, which will allow us to test GeNeuro's treatment for the neuropsychiatric forms of Long-COVID," said Jess Martin-Garcia, CEO of GeNeuro.

Key Points: 
  • "We are extremely grateful for this funding from the FOPH, which will allow us to test GeNeuro's treatment for the neuropsychiatric forms of Long-COVID," said Jess Martin-Garcia, CEO of GeNeuro.
  • Our approach is one of the first concrete leads to explain these problems, and also potentially to treat them with temelimab, GeNeuro's anti-W-ENV antibody."
  • This may allow early identification and treatment of patients who could benefit from anti-W-ENV therapy with temelimab.
  • Based in Geneva, Switzerland, and with an R&D center in Lyon, France, GeNeuro holds the rights to 17 patent families that protect its technology.

GeNeuro and Northwestern University Enter Into a Research Collaboration on HERV-W ENV in Long-haul COVID

Retrieved on: 
Friday, September 24, 2021
Research, Genetics, Clinical Trials, Biotechnology, Health, University, Pharmaceutical, Science, Education, Blood, International Center, Northwestern University, Patent, Lists of diseases, Research, Endothelium, Degenerative disease, Euronext Paris, Pediatric acute-onset neuropsychiatric syndrome, HERV-W, DNA, Patient, COVID, Lymphocyte, Disease, Leadership, COVID-19, Technology, Northwestern Memorial Hospital, Rufus Herve Bacote, Severe acute respiratory syndrome coronavirus 2, Brain, Northwestern Medicine, CIRI, Neurodegeneration, Multiple sclerosis, Neuro, Pharmaceutical industry, Vaccine, Medical imaging, W-ENV and COVID-19, GeNeuro, W-ENV AND COVID-19, GENEURO

Northwestern University is a pioneer in the comprehensive treatment of long-haul COVID-19 symptomatology, having established a Neuro COVID-19 Clinic at Northwestern Memorial Hospital as early as May 2020.

Key Points: 
  • Northwestern University is a pioneer in the comprehensive treatment of long-haul COVID-19 symptomatology, having established a Neuro COVID-19 Clinic at Northwestern Memorial Hospital as early as May 2020.
  • The purpose of the research agreement is to establish evidence of W-ENV expression on the transcriptional and protein level, to ascertain whether this protein can be a blood biomarker of neurological complications of long-haul COVID.
  • This research agreement complements the previously announced efforts in the long-haul COVID field that GeNeuro has launched in Europe with Fondation FondaMental and the CIRI (International Center for Infectiology Research, Lyon, France).
  • GeNeuro is based in Geneva, Switzerland and has R&D facilities in Lyon, France.

Octapharma Launches Phase 3 Superiority Study for Pediatric Acute-onset Neuropsychiatric Syndrome

Retrieved on: 
Thursday, September 3, 2020
Biotechnology, Pharmaceutical, Teens, Health, Mental health, Children, Consumer, Clinical trials, Drugs, Organ systems, Health, Childhood psychiatric disorders, RTT, Neurological disorders, Tourette syndrome, Autoimmune diseases, PANS, Pediatric acute-onset neuropsychiatric syndrome, Octapharma, Pandas

Octapharma has launched a phase 3, multicenter superiority study to compare the effectiveness of PANZYGA (immune globulin intravenous, human - ifas) 10% Liquid Preparation versus placebo in patients with pediatric acute-onset neuropsychiatric syndrome (PANS).

Key Points: 
  • Octapharma has launched a phase 3, multicenter superiority study to compare the effectiveness of PANZYGA (immune globulin intravenous, human - ifas) 10% Liquid Preparation versus placebo in patients with pediatric acute-onset neuropsychiatric syndrome (PANS).
  • PANS is a newly defined symptom-based condition that mainly occurs in children and adolescents, said Octapharma USA President Flemming Nielsen.
  • We are hopeful that PANZYGA can make a difference in the lives of children and adolescents impacted by the syndrome.
  • Approximately 30 study sites are planned for the prospective, randomized, double-blind, parallel group, placebo-controlled superiority study.

New Video from PANDAS Network Shows How Infections Attack Brains and Result in Devastating PANDAS/PANS Symptoms

Retrieved on: 
Monday, May 18, 2020
Childhood psychiatric disorders, Medical specialties, Health, Medicine, Neurological disorders, Pediatric acute-onset neuropsychiatric syndrome, Syndromes, Autoimmune diseases, Pandas, PANS, Streptococcus, Autoimmunity

The conditions are caused by an autoimmune reaction triggered by infections such as strep throat, walking pneumonia, viruses and Lyme disease, which result in inflammation of the child's brain.

Key Points: 
  • The conditions are caused by an autoimmune reaction triggered by infections such as strep throat, walking pneumonia, viruses and Lyme disease, which result in inflammation of the child's brain.
  • That attack causes neuroinflammation and neuronal dysfunction, leading to the abrupt onset of severe neurological and/or psychiatric symptoms.
  • "The loss of taste and smell in BGE patients was an unexpected clue," said Diana Pohlman, director of the nonprofit PANDAS Network .
  • PANDAS Network is dedicated to improving the diagnosis and treatment of children with PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections) and PANS (Pediatric Acute-onset Neuropsychiatric Syndrome).

Moleculera Labs’ Study Demonstrates Clinical Utility and Accuracy of the Cunningham Panel in Patients With Symptoms of Autoimmune Encephalopathy

Retrieved on: 
Wednesday, January 8, 2020
Mental health, Health, Infectious diseases, Research, Science, Pharmaceutical, Biotechnology, Medical specialties, Organ systems, Childhood psychiatric disorders, Autoimmune diseases, Nervous system, Biology of obsessive–compulsive disorder, Pandas, Tourette syndrome, Encephalopathy, Autoimmunity, Pediatric acute-onset neuropsychiatric syndrome, the Cunningham Panel™, Autoimmune Encephalopathy, Moleculera Labs

Moleculera Labs, Inc., a precision medicine, autoimmune neurobiology company, today announced the online publication of a study in the Journal of Neuroimmunology that shows a correlation between the accuracy and sensitivity of the Cunningham Panel results and symptom resolution in patients with an infection-triggered autoimmune encephalopathy.

Key Points: 
  • Moleculera Labs, Inc., a precision medicine, autoimmune neurobiology company, today announced the online publication of a study in the Journal of Neuroimmunology that shows a correlation between the accuracy and sensitivity of the Cunningham Panel results and symptom resolution in patients with an infection-triggered autoimmune encephalopathy.
  • Autoimmune encephalopathy is an infection-triggered immune response against portions of the brain or nervous system which can result in a variety of neurologic or psychiatric symptoms.
  • This case series included 58 patients diagnosed with PANS/PANDAS, an infection-triggered autoimmune encephalopathy, who were tested with the Cunningham Panel pre- and post-treatment and results were compared with their reported neuropsychiatric symptoms.
  • The panel is available worldwide from Moleculera Labs, and can be ordered by licensed healthcare practitioners or clinicians authorized to order laboratory tests.